Clinical Trial Update: Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial exploring adjuvant PD-1 antibody in combination with capecitabine for intrahepatic cholangiocarcinoma at high risk of recurrence after surgery …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Fudan University | Conditions: Cholangiocarcinoma, Intrahepatic | Phase 1, Phase 2 | Status: UNKNOWN